FindTrial
Sign In

The effect of Montecukast on Nephrotic Syndrome

Evaluation the Effect of Montelukast as an adjunctive therapy on Treatment results (Proteinuria, Edema, Albumin Level) of Nephrotic Syndrome in Children

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130518013366N13
Enrollment
40
Registered
2020-03-24
Start date
2019-09-08
Completion date
Unknown
Last updated
2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrotic Syndrome. Nephrotic syndrome

Interventions

Intervention 1: Intervention group: In these patients, in addition to the usual treatment of nephrotic syndrome including 60 mg / m2 / day is 60 mg of prednisolone (maximum dose of 80 mg / m2 / day) f

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 15 Years

Inclusion criteria

Inclusion criteria: Affected to Nephrotic Syndrome

Exclusion criteria

Exclusion criteria: Underlying blood disease Underlying liver disease

Design outcomes

Primary

MeasureTime frame
Albumin level. Timepoint: Before treatment and 2 months after the administration of Montelukast. Method of measurement: Blood test.;Urinary tract Infection. Timepoint: Before treatment and 2 months after the administration of Montelukast. Method of measurement: Urine test.;Edema. Timepoint: Before treatment and 2 months after the administration of Montelukast. Method of measurement: Physical examination.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh javidi

Arak University of Medical Sciences

Fatemehjavidi@yahoo.com+98 86 3313 5075

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026